Go to deals
Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

Parties

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Nicola Vulcano

Director
Milan, Italy
Oaklins Italy

Marco Valsecchi

Associate
Milan, Italy
Oaklins Italy

Rita Vizzi

Analyst
Milan, Italy
Oaklins Italy

Related deals

Ebidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Private Equity | Industrial Machinery & Components

Ebidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment

Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.

Learn more
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Healthcare

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Learn more
Aedes has finalized a rights issue
Real Estate

Aedes has finalized a rights issue

Aedes S.p.A. has successfully finalized a rights issue to support the objectives of the group’s 2024-2028 business plan and the relaunch of its business.

Learn more